APA (7th ed.) Citation

Chang, X., Li, X., Sun, P., Li, Z., Sun, P., & Ning, S. (2024). HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: A real-world study. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12233-6

Chicago Style (17th ed.) Citation

Chang, Xu, Xinge Li, Peng Sun, Zhenfeng Li, Pengfei Sun, and Shangkun Ning. "HAIC Combined with Lenvatinib Plus PD-1 Versus Lenvatinib Plus PD-1 in Patients with High-risk Advanced HCC: A Real-world Study." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12233-6.

MLA (9th ed.) Citation

Chang, Xu, et al. "HAIC Combined with Lenvatinib Plus PD-1 Versus Lenvatinib Plus PD-1 in Patients with High-risk Advanced HCC: A Real-world Study." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12233-6.